German drugs and liquid crystals marker Merck KGaA posted a spectacular set of second-quarter 2010 results yesterday, beating consensus forecasts and causing a 5.9% rise to 68.08 euros in its share price, after reporting a 69% leap to 183.4 million euros ($235.1 million) in its net profit.
Profit after tax rose 70.1% to 326.2 million euros. Earnings per share were up 69.1% at 0.84 euros, total revenues jumped 15.6% to 2.21 billion euros, and operating results were 76.8% higher at 326.2 million euros.
"The pleasing results of the second quarter ...show that our excellent first quarter was setting the course for the year," said executive board chairman Karl-Ludwig Kley. "Therefore, we feel comfortable to again raise our guidance for 2010 and now expect the Merck Group, including Millipore [the US firm that Merck bought for $7.2 billion; The Pharma Letter March 1], to increase total revenues by 21% and the operating result by 90%," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze